Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 21;23(27):4910-4919.
doi: 10.3748/wjg.v23.i27.4910.

Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion

Affiliations

Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion

Takanobu Takata et al. World J Gastroenterol. .

Abstract

Aim: To determine the possibility that diabetes mellitus promotes pancreatic ductal adenocarcinoma via glyceraldehyde (GA)-derived advanced glycation-end products (GA-AGEs).

Methods: PANC-1, a human pancreatic cancer cell line, was treated with 1-4 mmol/L GA for 24 h. The cell viability and intracellular GA-AGEs were measured by WST-8 assay and slot blotting. Moreover, immunostaining of PANC-1 cells with an anti-GA-AGE antibody was performed. Western blotting (WB) was used to analyze the molecular weight of GA-AGEs. Heat shock proteins 90α, 90β, 70, 27 and cleaved caspase-3 were analyzed by WB. In addition, PANC-1 cells were treated with GA-AGEs-bovine serum albumin (GA-AGEs-BSA), as a model of extracellular GA-AGEs, and proliferation of PANC-1 cells was measured.

Results: In PANC-1 cells, GA induced the production of GA-AGEs and cell death in a dose-dependent manner. PANC-1 cell viability was approximately 40% with a 2 mmol/L GA treatment and decreased to almost 0% with a 4 mmol/L GA treatment (each significant difference was P < 0.01). Cells treated with 2 and 4 mmol/L GA produced 6.4 and 21.2 μg/mg protein of GA-AGEs, respectively (P < 0.05 and P < 0.01). The dose-dependent production of some high-molecular-weight (HMW) complexes of HSP90β, HSP70, and HSP27 was observed following administration of GA. We considered HMW complexes to be dimers and trimers with GA-AGEs-mediated aggregation. Cleaved caspase-3 could not be detected with WB. Furthermore, 10 and 20 μg/mL GA-AGEs-BSA was 27% and 34% greater than that of control cells, respectively (P < 0.05 and P < 0.01).

Conclusion: Although intracellular GA-AGEs induce pancreatic cancer cell death, their secretion and release may promote the proliferation of other pancreatic cancer cells.

Keywords: Glyceraldehyde-derived advanced glycation-end products; Pancreatic ductal adenocarcinoma; Tumor promotion.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: The authors declare no competing financial interests.

Figures

Figure 1
Figure 1
Analysis of cell viability, quantity of glyceraldehyde-derived advanced glycation-end products, immunostaining of glyceraldehyde-derived advanced glycation-end products, and molecular weight of glyceraldehyde-derived advanced glycation-end products in PANC-1 cells treated with glyceraldehyde for 24 h. A: Cell viability was assessed by the WST-8 assay. This assay was performed for three independent experiments. One assay was performed for n = 7. Data are shown as mean ± SD (n = 7); B: Slot blotting analysis of intracellular glyceraldehyde (GA)-derived advanced glycation-end products (GA-AGEs). Cell lysates (2.0 μg of protein/lane) were blotted onto polyvinylidene difluoride (PVDF) membranes. The amount of GA-AGEs was calculated based on a standard curve for GA-AGEs-BSA. Slot blotting was performed for three independent experiments. Data are shown as mean ± SD (n = 3); C: Immunostaining of GA-AGEs in PANC-1 cells. Cells were treated with 0, 1, 2 and 4 mmol/L GA. The arrow indicates the area stained by the anti-GA-AGE antibody. The scale bar represents 200 μm; D: Western blotting analysis of intracellular GA-AGEs in PANC-1 cells. Cell lysates (15 μg of proteins/lane) were loaded on a 40-150 g/L polyacrylamide gradient gel. Proteins on the PVDF membrane were probed with anti-GA-AGE and anti-GA-3-phosphate dehydrogenase (GAPDH) antibodies. The molecular weight of GA-AGEs was calculated based on a single logarithmic chart used by the molecular marker. GAPDH was used as the loading control. WB was performed for two independent experiments. A and B: P values were based on Dunnett’s test. aP < 0.05, bP < 0.01 vs control.
Figure 2
Figure 2
Western blotting analysis of HSP90α and HSP90β. PANC-1 cell lysates (15 μg of proteins/lane) were loaded on a 40-150 g/L polyacrylamide gradient gel. A: Proteins on the polyvinylidene difluoride (PVDF) membrane were probed with anti-HSP90α and anti-GAPDH antibodies; B: Expression levels of HSP90α were normalized with GAPDH; C: Proteins on the PVDF membrane were probed with anti-HSP90β and anti-GAPDH antibodies. A band of 173 kDa HSP90β only appeared in PANC-1 cells treated with GA; D: Expression levels of the monomer HSP90β were normalized with GAPDH; E: The 173 kDa HSP90β/total HSP90β ratio. A and C: Western blotting was performed for three independent experiments. GAPDH was used as the loading control; B, D and E: Data are shown as mean ± SD (n = 3). P values were based on Dunnett’s test. aP < 0.05, bP < 0.01 vs control. GA: Glyceraldehyde.
Figure 3
Figure 3
Western blotting analysis of HSP70 and HSP27. PANC-1 cell lysates (15 μg of proteins/lane) were loaded on a 40-150 g/L polyacrylamide gradient gel. A: Proteins on the polyvinylidene difluoride (PVDF) membrane were probed with anti-HSP70 and anti-GA-3 phosphate dehydrogenase (anti-GAPDH) antibodies. We found four high-molecular-weight (HMW) complexes of HSP70s only in PANC-1 cells treated with GA. Their MWs were 138, 155, 184 and 244 kDa; B: Expression levels of the monomer HSP70 were normalized with GAPDH; C-F: The 138 kDa HSP70/total HSP70, 155 kDa HSP70/total HSP70, 184 kDa HSP70/total HSP70, and 244 kDa HSP70/total HSP70 ratios; G: Proteins on the PVDF membrane were probed with anti-HSP27 and anti-GAPDH antibodies. A HMW complex with a MW of 54 kDa appeared only in PANC-1 cells treated with GA; H: Expression levels of the monomer HSP27 were normalized with GAPDH; I: The 54 kDa HSP27/total HSP27 ratio; A and G: WB was performed for three independent experiments. GAPDH was used as a loading control. B-F, H, I: Data are shown as mean ± SD (n = 3). P values were based on Dunnett’s test. aP < 0.05, bP < 0.01 vs control. GA: Glyceraldehyde.
Figure 4
Figure 4
Western blotting analysis of cleaved caspase-3. PANC-1 cell lysates (15 μg of protein/lane) and Jurkat cell lysates (10 μg of protein/lane) were loaded on a 40-150 g/L polyacrylamide gradient gel. Proteins on the PVDF membrane were probed with anti-cleaved caspase-3 and anti-GA-3 phosphate dehydrogenase (anti-GAPDH) antibodies. U: The lysate of Jurkat cells not treated with cytochrome c. T: The lysate of Jurkat cells treated with cytochrome c. Western blotting was performed for three independent experiments. GAPDH was used as a loading control. GA: Glyceraldehyde.
Figure 5
Figure 5
Analysis of the proliferation of PANC-1 cells treated with glyceraldehyde-derived advanced glycation-end products-bovine serum albumin. PANC-1 cells were treated with 10 and 20 μg/mL of non-glycated control BSA and glyceraldehyde-derived advanced glycation-end products-bovine serum albumin (GA-AGEs-BSA) to then be incubated for 24 h. This assay was performed for two independent experiments. One assay was performed for n = 7. Cell proliferation was assessed by the WST-8 assay. Data are shown as mean ± SD (n = 7). P values were based on the Student’s t-test. aP < 0.05, bP < 0.01 vs control.

Similar articles

Cited by

References

    1. Shimasaki T, Yamamoto S, Ishigaki Y, Takata T, Arisawa T, Motoo Y, Tomosug N, Minamoto T. Identification and functional analysis of an EMT-accelerating factor induced in pancreatic cancer cells by anticancer agent. Suizo. 2016;31:76–84.
    1. Wada K, Takaori K, Traverso LW, Hruban RH, Furukawa T, Brentnall TA, Hatori T, Sano K, Takada T, Majima Y, et al. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. J Hepatobiliary Pancreat Sci. 2013;20:557–566. - PubMed
    1. Sinnett-Smith J, Kisfalvi K, Kui R, Rozengurt E. Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun. 2013;430:352–357. - PMC - PubMed
    1. Takeuchi M. Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases. Diagnostics (Basel) 2016;6:pii: E23. - PMC - PubMed
    1. Bobrowski A, Spitzner M, Bethge S, Mueller-Graf F, Vollmar B, Zechner D. Risk factors for pancreatic ductal adenocarcinoma specifically stimulate pancreatic duct glands in mice. Am J Pathol. 2013;182:965–974. - PubMed

MeSH terms

Substances